Dihydromyricetin Enhances the Chemo-Sensitivity of Nedaplatin via Regulation of the p53/Bcl-2 Pathway in Hepatocellular Carcinoma Cells.
Chemotherapy is an effective weapon in the battle against cancer. Nedaplatin (NDP) is an improved platinum-containing drug with lower cytotoxicity than other similar drugs. However, the repeated use of NDP results in substantial hepatocyte damage as well as drug resistance in hepatocellular carcinom...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4411137?pdf=render |
id |
doaj-d523e7d2f89248f398adc79aefe8b07c |
---|---|
record_format |
Article |
spelling |
doaj-d523e7d2f89248f398adc79aefe8b07c2020-11-25T02:01:10ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01104e012499410.1371/journal.pone.0124994Dihydromyricetin Enhances the Chemo-Sensitivity of Nedaplatin via Regulation of the p53/Bcl-2 Pathway in Hepatocellular Carcinoma Cells.Lianggui JiangQingyu ZhangHao RenSheng MaCaiJie LuBin LiuJie LiuJian LiangMingyi LiRunzhi ZhuChemotherapy is an effective weapon in the battle against cancer. Nedaplatin (NDP) is an improved platinum-containing drug with lower cytotoxicity than other similar drugs. However, the repeated use of NDP results in substantial hepatocyte damage as well as drug resistance in hepatocellular carcinoma (HCC) cases. Therefore, the development of effective chemotherapy strategies that enhance tumor sensitivity to chemotherapeutics and reduce the secondary damage to liver cells is urgently needed. Dihydromyricetin (DHM), a natural flavonoid compound, has been shown to have antitumor activity with no obvious toxicity to normal cells in vitro and in vivo. In this study, DHM and NDP were combined to treat liver cancer cells; we found that DHM functions as a protector of normal cells compared with the use of NDP alone. In addition, the synergy of DHM with NDP enhanced the effect of NDP on the induction of HCC cell apoptosis. We found that the combination caused clear changes in the level of reactive oxygen species (ROS). Furthermore, we demonstrated that the combination of DHM and NDP activated the p53/Bcl-2 signaling pathway, which resulted in mitochondrial dysfunction and induced cell death and growth inhibition in HCC cells.http://europepmc.org/articles/PMC4411137?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Lianggui Jiang Qingyu Zhang Hao Ren Sheng Ma CaiJie Lu Bin Liu Jie Liu Jian Liang Mingyi Li Runzhi Zhu |
spellingShingle |
Lianggui Jiang Qingyu Zhang Hao Ren Sheng Ma CaiJie Lu Bin Liu Jie Liu Jian Liang Mingyi Li Runzhi Zhu Dihydromyricetin Enhances the Chemo-Sensitivity of Nedaplatin via Regulation of the p53/Bcl-2 Pathway in Hepatocellular Carcinoma Cells. PLoS ONE |
author_facet |
Lianggui Jiang Qingyu Zhang Hao Ren Sheng Ma CaiJie Lu Bin Liu Jie Liu Jian Liang Mingyi Li Runzhi Zhu |
author_sort |
Lianggui Jiang |
title |
Dihydromyricetin Enhances the Chemo-Sensitivity of Nedaplatin via Regulation of the p53/Bcl-2 Pathway in Hepatocellular Carcinoma Cells. |
title_short |
Dihydromyricetin Enhances the Chemo-Sensitivity of Nedaplatin via Regulation of the p53/Bcl-2 Pathway in Hepatocellular Carcinoma Cells. |
title_full |
Dihydromyricetin Enhances the Chemo-Sensitivity of Nedaplatin via Regulation of the p53/Bcl-2 Pathway in Hepatocellular Carcinoma Cells. |
title_fullStr |
Dihydromyricetin Enhances the Chemo-Sensitivity of Nedaplatin via Regulation of the p53/Bcl-2 Pathway in Hepatocellular Carcinoma Cells. |
title_full_unstemmed |
Dihydromyricetin Enhances the Chemo-Sensitivity of Nedaplatin via Regulation of the p53/Bcl-2 Pathway in Hepatocellular Carcinoma Cells. |
title_sort |
dihydromyricetin enhances the chemo-sensitivity of nedaplatin via regulation of the p53/bcl-2 pathway in hepatocellular carcinoma cells. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2015-01-01 |
description |
Chemotherapy is an effective weapon in the battle against cancer. Nedaplatin (NDP) is an improved platinum-containing drug with lower cytotoxicity than other similar drugs. However, the repeated use of NDP results in substantial hepatocyte damage as well as drug resistance in hepatocellular carcinoma (HCC) cases. Therefore, the development of effective chemotherapy strategies that enhance tumor sensitivity to chemotherapeutics and reduce the secondary damage to liver cells is urgently needed. Dihydromyricetin (DHM), a natural flavonoid compound, has been shown to have antitumor activity with no obvious toxicity to normal cells in vitro and in vivo. In this study, DHM and NDP were combined to treat liver cancer cells; we found that DHM functions as a protector of normal cells compared with the use of NDP alone. In addition, the synergy of DHM with NDP enhanced the effect of NDP on the induction of HCC cell apoptosis. We found that the combination caused clear changes in the level of reactive oxygen species (ROS). Furthermore, we demonstrated that the combination of DHM and NDP activated the p53/Bcl-2 signaling pathway, which resulted in mitochondrial dysfunction and induced cell death and growth inhibition in HCC cells. |
url |
http://europepmc.org/articles/PMC4411137?pdf=render |
work_keys_str_mv |
AT liangguijiang dihydromyricetinenhancesthechemosensitivityofnedaplatinviaregulationofthep53bcl2pathwayinhepatocellularcarcinomacells AT qingyuzhang dihydromyricetinenhancesthechemosensitivityofnedaplatinviaregulationofthep53bcl2pathwayinhepatocellularcarcinomacells AT haoren dihydromyricetinenhancesthechemosensitivityofnedaplatinviaregulationofthep53bcl2pathwayinhepatocellularcarcinomacells AT shengma dihydromyricetinenhancesthechemosensitivityofnedaplatinviaregulationofthep53bcl2pathwayinhepatocellularcarcinomacells AT caijielu dihydromyricetinenhancesthechemosensitivityofnedaplatinviaregulationofthep53bcl2pathwayinhepatocellularcarcinomacells AT binliu dihydromyricetinenhancesthechemosensitivityofnedaplatinviaregulationofthep53bcl2pathwayinhepatocellularcarcinomacells AT jieliu dihydromyricetinenhancesthechemosensitivityofnedaplatinviaregulationofthep53bcl2pathwayinhepatocellularcarcinomacells AT jianliang dihydromyricetinenhancesthechemosensitivityofnedaplatinviaregulationofthep53bcl2pathwayinhepatocellularcarcinomacells AT mingyili dihydromyricetinenhancesthechemosensitivityofnedaplatinviaregulationofthep53bcl2pathwayinhepatocellularcarcinomacells AT runzhizhu dihydromyricetinenhancesthechemosensitivityofnedaplatinviaregulationofthep53bcl2pathwayinhepatocellularcarcinomacells |
_version_ |
1724958288332718080 |